Oligonucleotide Synthesis Market Share To Reach Scalable Heights Of Growth
The global oligonucleotide synthesis market is experiencing strong growth as oligonucleotides become increasingly important in therapeutics, molecular diagnostics, genomics, sequencing, gene editing, and life sciences research. Oligonucleotides are short DNA or RNA sequences that can be chemically or enzymatically synthesized for applications ranging from PCR and genetic testing to advanced medicines and CRISPR-based technologies. Growing investment in precision medicine and nucleic acid therapies is creating significant opportunities for synthesis service providers and technology manufacturers.
According to Grand View Research, the global oligonucleotide synthesis market was valued at USD 3.6 billion in 2025 and is estimated to reach USD 4.1 billion in 2026. The market is projected to reach USD 10.9 billion by 2033, expanding at a CAGR of 14.9% from 2026 to 2033. North America dominated the market with a 40.4% revenue share in 2025, while Asia Pacific is expected to register the fastest growth at a CAGR of 17.9%.
Market Size and Growth Projections
The growing use of nucleic acid based therapeutics is one of the primary factors supporting market expansion. Oligonucleotides are used in antisense oligonucleotides, small interfering RNA therapies, mRNA applications, gene editing, and other advanced therapeutic approaches. Increasing regulatory approvals and expanding clinical pipelines for genetic, oncology, and infectious disease applications are further supporting demand.
The market is expected to increase from USD 4.1 billion in 2026 to USD 10.9 billion by 2033. Pharmaceutical and biotechnology companies are also increasingly outsourcing synthesis activities to specialized providers because advanced therapeutic designs often require customized sequences, chemical modifications, long-chain oligonucleotides, and GMP-grade manufacturing capabilities.
Key Market Data (2025 Projections)
- Market Size (2025): USD 3.6 billion
- Market Size (2026): USD 4.1 billion
- Projected Value (2033): USD 10.9 billion
- Market CAGR (2026 to 2033): 14.9%
- Dominant Region: North America
- North America Revenue Share (2025): 40.4%
- Fastest-growing Region: Asia Pacific
- Asia Pacific CAGR: 17.9%
Core Applications and Impact
Oligonucleotides have become essential components of modern molecular biology. PCR primers represented the largest application segment in 2025, accounting for approximately 20.6% of market revenue. PCR, qPCR, RT-PCR, and digital PCR depend on accurately designed primers to amplify specific genetic sequences. Their use in genetic testing, infectious disease detection, research, and molecular diagnostics continues to generate demand.
Sequencing is expected to be among the fastest-growing application areas. Improvements in next-generation sequencing, bioinformatics, pathogen detection, and genetic analysis are increasing the requirement for high-quality oligonucleotides. Advances in synthesis technology are also enabling the production of longer and more complex DNA sequences.
Oligonucleotides are also increasingly important in therapeutic development. Antisense oligonucleotides and siRNA therapies can influence gene expression by targeting specific RNA sequences. This has opened opportunities for treating genetic disorders, metabolic diseases, neurological conditions, and other complex diseases.
Emerging Core Trends
- One of the most important trends is the growing adoption of nucleic acid therapeutics. The expanding pipeline of antisense, siRNA, mRNA, and gene-editing therapies is increasing demand for specialized synthesis capabilities. Manufacturers are investing in technologies capable of producing high-purity and chemically modified sequences at research, clinical, and commercial scales.
- CRISPR gene editing is another important technology influencing the industry. Oligonucleotides are used in guide RNA and other components of gene-editing workflows. Grand View Research identifies CRISPR as one of the most influential and innovative technologies affecting biotechnology and oligonucleotide synthesis.
- Outsourcing is also gaining momentum. Pharmaceutical and biotechnology companies increasingly rely on specialized synthesis providers to reduce infrastructure requirements and access advanced manufacturing capabilities. The services segment accounted for 1% of market revenue in 2025 and is also projected to grow at the fastest rate during the forecast period.
- Another emerging trend is enzymatic DNA synthesis. Companies are investing in alternative synthesis technologies that can potentially improve scalability and support the production of longer DNA sequences.
Looking for more specific insights? Customize this report to suite your business needs
Geographical Landscape
North America dominated the global market with a 40.4% revenue share in 2025. The region benefits from a strong pharmaceutical and biotechnology industry, extensive genomics research, advanced healthcare infrastructure, and significant investments in molecular diagnostics and precision medicine.
The U.S. represents the leading market within North America because of its strong research ecosystem and concentration of pharmaceutical, biotechnology, and specialized synthesis companies.
Europe also represents a significant market, supported by government-funded research programs, biotechnology development, genomics investments, and increasing adoption of oligonucleotide therapeutics.
Asia Pacific is expected to be the fastest-growing regional market, with a projected 17.9% CAGR from 2026 to 2033. China, Japan, and India are important growth markets because of increasing biotechnology investments, research infrastructure development, and government support for genomics and personalized medicine. China held the largest country-level share in the region in 2025.
Top Industry Players
The global oligonucleotide synthesis market includes biotechnology companies, life sciences suppliers, pharmaceutical technology providers, and specialized synthesis organizations.
Major industry participants include:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Revvity Discovery Limited
- Agilent Technologies, Inc.
- Bio-Synthesis, Inc.
- Kaneka Eurogentec S.A.
- LGC Biosearch Technologies
- Biolegio
- Twist Bioscience
Explore our dedicated business services:
- US Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
- Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
- Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
- Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
- Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
- Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
- Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.
About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.
Comments
Post a Comment